Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
1,359 stopped studies mapped to Non-Hodgkin Lymphoma and descendants · 89% state a reason
Over the 1,359 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT04621955 | Observational Study of Home Administration of Carfilzomib(KARE-2) | — | withdrawn | Nov 9, 2020 | Universitaire Ziekenhuizen KU Leuven | Not possible to conduct study | Other (stated, no rule matched) |
| NCT03033316 | A Evaluation of the Safety of Oncocort IV Pegylated Liposomal Dexamethasone Phosphate in…(AMETHYST) | Phase 1 / Phase 2 | terminated | Jan 26, 2017 | Enceladus Pharmaceuticals BV | Patient enrolment issues | Enrollment / accrual |
| NCT04094766 | Safety and Efficacy of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy in R/R… | Phase 1 | withdrawn | Sep 19, 2019 | Second Affiliated Hospital of Xi'an Jiaotong University | Production plan adjustment | Other (stated, no rule matched) |
| NCT04230330 | Nivolumab in Combination With GDP/ L-asparaginase in NK/ T-cell Lymphoma | Phase 1 | withdrawn | Jan 18, 2020 | National Cancer Centre, Singapore | PI has left the institution. | Other (stated, no rule matched) |
| NCT03287804 | APRIL CAR T Cells (AUTO2) Targeting BCMA and TACI for the Treatment of Multiple Myeloma(APRIL) | Phase 1 / Phase 2 | terminated | Sep 19, 2017 | Autolus Limited | Preliminary efficacy seen to date following treatment with AUTO2 has been determined not sufficient… | Efficacy / futility |
| NCT04503538 | Telemedicine for Early Detection of Cytokine Release Syndrome and Neurotoxicity | N/A | withdrawn | Aug 7, 2020 | Wake Forest University Health Sciences | Principal investigator decided not to pursue trial | Investigator |
| NCT03779555 | Lenalidomide Adherence in Older Adults | — | terminated | Dec 19, 2018 | Washington University School of Medicine | Principal Investigator left the university | Investigator |
| NCT02012231 | Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in… | Phase 1 | terminated | Dec 16, 2013 | Fore Biotherapeutics | not stated | Not stated |
| NCT03037645 | Safety, PK, PD, and Antitumor Activity of Vecabrutinib (SNS-062) in B Lymphoid Cancers | Phase 1 / Phase 2 | terminated | Jan 31, 2017 | Sunesis Pharmaceuticals | Phase 1b portion completed. Sponsor decided not to proceed with P2 portion of study. Vecabrutinib… | Sponsor / business decision |
| NCT03553914 | PLM60 for Peripheral T Cell Lymphoma (PTCL) | Phase 1 / Phase 2 | withdrawn | Jun 12, 2018 | Conjupro Biotherapeutics, Inc. | IND Inactive Status | Other (stated, no rule matched) |
| NCT03963024 | Treosulfan-TMI Conditioning and Rapamycin GvHD Prophylaxis Before Allo-HSCT(TrRaMM-TMI) | Phase 1 | terminated | May 24, 2019 | IRCCS San Raffaele | low rate of enrolment | Enrollment / accrual |
| NCT04293900 | Diet, Physical Activity and Body Composition Changes During R-CHOP(R-CHOP-OS) | — | withdrawn | Mar 3, 2020 | George Washington University | Study never started due to COVID pandemic and lack of study funding. | COVID-19 / pandemic |
| NCT00577161 | Fludarabine, Pixantrone and Rituximab vs Fludarabine and Rituximab forRelapsed or… | Phase 3 | withdrawn | Dec 19, 2007 | CTI BioPharma | closed to enrollment | Enrollment / accrual |
| NCT02786485 | Study of Matched Unrelated Donor T Cell Infusion for Hematologic Malignancies After… | Phase 1 | withdrawn | Jun 1, 2016 | Bellicum Pharmaceuticals | not stated | Not stated |
| NCT02991898 | Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies | Phase 2 | terminated | Dec 14, 2016 | Masonic Cancer Center, University of Minnesota | Considering new technology for product. | Other (stated, no rule matched) |
| NCT03925428 | Testing a New Anti-cancer Drug Combination, Entinostat and GSK525762C, for Advanced and… | Phase 1 | withdrawn | Apr 24, 2019 | National Cancer Institute (NCI) | Other - Protocol moved to Disapproved | Other (stated, no rule matched) |
| NCT02952573 | Testing JNJ-42756493 In Combination With Dexamethasone in Multiple Myeloma That Came Back… | Phase 2 | terminated | Nov 2, 2016 | University Health Network, Toronto | Low patient accrual | Enrollment / accrual |
| NCT01658007 | Pilot Study Of Sirolimus Plus Multiagent Chemotherapy For Relapsed/Refractory Acute…(SIR-MO-1101) | Early Phase 1 | terminated | Aug 6, 2012 | Children's Hospital Medical Center, Cincinnati | Slow Accrual | Enrollment / accrual |
| NCT03225924 | Study of Entospletinib (ENTO) in Newly Diagnosed DLBCL Patients With aaIPI>=1 Treated by… | Phase 1 / Phase 2 | terminated | Jul 21, 2017 | The Lymphoma Academic Research Organisation | Stop of drug development | Other (stated, no rule matched) |
| NCT01460602 | Velcade, Nipent, Rituxan (VNR) in Subjects With Relapsed Follicular, Marginal Zone, and… | Phase 1 / Phase 2 | withdrawn | Oct 27, 2011 | Louisiana State University Health Sciences Center Shreveport | Investigator has relocated to MD Anderson | Investigator |
| NCT03000660 | Trial of Venetoclax (ABT-199) and Dexamethasone for Relapsed or Refractory Systemic AL… | Phase 1 | terminated | Dec 22, 2016 | Tufts Medical Center | partial clinical hold per FDA | Other (stated, no rule matched) |
| NCT04355039 | INCB053914 and Pomalidomide With Dexamethasone for Relapsed and/or Refractory Multiple… | Phase 1 | withdrawn | Apr 21, 2020 | Medical College of Wisconsin | Terminated for lack of funding. | Funding |
| NCT00674427 | Trial of Donor Lymphocyte Infusion (DLI) and Activated DLI Following Relapse After… | Phase 1 | terminated | May 7, 2008 | University of Pennsylvania | Insufficient funds | Funding |
| NCT02875067 | Safety & Efficacy Study of Combination of Pembrolizumab and Lenalidomide, in Patients… | Phase 1 / Phase 2 | terminated | Aug 23, 2016 | NYU Langone Health | Merck's decision for early termination of the data | Other (stated, no rule matched) |
| NCT04233697 | Copanlisib in Combination With Romidepsin in Patients With Relapsed or Refractory Mature… | Phase 1 | withdrawn | Jan 18, 2020 | Columbia University | Investigator left institution | Investigator |
| NCT01973062 | Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Primary Central Nervous System… | Phase 2 | terminated | Oct 31, 2013 | Case Comprehensive Cancer Center | Funding Unavailable | Funding |
| NCT03506802 | TCR Genetically Engineered PBMC and PBSC After Melphalan Conditioning Regimen in Treating…(NYSCT MM) | Phase 1 | withdrawn | Apr 24, 2018 | Jonsson Comprehensive Cancer Center | No Participants Enrolled | Enrollment / accrual |
| NCT04439305 | Testing Dasatinib as a Potential Targeted Treatment in Cancers With DDR2 Genetic Changes… | Phase 2 | withdrawn | Jun 19, 2020 | National Cancer Institute (NCI) | zero accrual | Enrollment / accrual |
| NCT03145870 | Prevalence of Asymptomatic Thrombosis in Multiple Myeloma | N/A | withdrawn | May 9, 2017 | Centre Hospitalier Universitaire, Amiens | investigator choice | Investigator |
| NCT03983486 | Rationale for Cytogenetic Risk Stratification by Imaging Flow Cytometry in Multiple…(CIF-PM) | — | withdrawn | Jun 12, 2019 | Centre Hospitalier Universitaire, Amiens | technical problem | Other (stated, no rule matched) |
| NCT01832727 | Phase 1b/2, Multicenter, Open-label Study of Oprozomib and Dexamethasone in Patients With… | Phase 1 / Phase 2 | terminated | Apr 16, 2013 | Amgen | Enrollment halted during phase 2 to reformulate the investigational product | Enrollment / accrual |
| NCT03003728 | 2015-10: Expanded Natural Killer Cells and Elotuzumab for High-Risk Myeloma Post-… | Phase 2 | withdrawn | Dec 28, 2016 | University of Arkansas | Withdrawal of study support | Other (stated, no rule matched) |
| NCT03617484 | Bortezomib in Combination With Ibrutinib in Ibrutinib Relapsed Mantle Cell Lymphoma | Phase 2 | withdrawn | Aug 6, 2018 | University of Michigan Rogel Cancer Center | Enrollment and/or interactions/interventions temporarily paused due to COVID-19 and expected to… | COVID-19 / pandemic |
| NCT00985907 | Doxil® + Melphalan + Velcade (DMV) in Relapsed/Refractory Multiple Myeloma(DMV) | Phase 1 / Phase 2 | terminated | Sep 29, 2009 | University of California, San Francisco | Low Accrual | Enrollment / accrual |
| NCT01796470 | Entospletinib in Combination With Idelalisib in Adults With Relapsed or Refractory… | Phase 2 | terminated | Feb 21, 2013 | Gilead Sciences | Study was terminated due to safety measures. | Safety / toxicity |
| NCT03492138 | Ixazomib, ONC201, and Dexamethasone in Relapsed/Refractory Multiple Myeloma | Phase 1 / Phase 2 | terminated | Apr 10, 2018 | Ajai Chari | Low enrollment | Enrollment / accrual |
| NCT02624986 | A Study of Idasanutlin in Combination With Obinutuzumab in Relapsed/Refractory (R/R)… | Phase 1 / Phase 2 | terminated | Dec 9, 2015 | Hoffmann-La Roche | Sponsor's decision to terminate the study after Phase 1; will not proceed with Phase 2. | Sponsor / business decision |
| NCT00303719 | Allogeneic Bone Marrow Transplantation Using Less Intensive Therapy | Phase 2 | terminated | Mar 17, 2006 | Masonic Cancer Center, University of Minnesota | IRB Study Closure | Other (stated, no rule matched) |
| NCT03436771 | Long-term Follow-up Study for Patients Previously Treated With a Juno CAR T-Cell Product | — | terminated | Feb 19, 2018 | Juno Therapeutics, a Subsidiary of Celgene | Eligible subjects will be enrolled in Celgene's long-term follow-up protocol for subjects… | Enrollment / accrual |
| NCT00632827 | Treatment of PTCL With Aggressive Induction Therapy Followed by Autologous SCT Using… | Phase 2 | terminated | Mar 11, 2008 | University of California, San Francisco | Manufacturing shortage of both Diftitox and Doxil | Drug supply |
| NCT03617224 | Pembrolizumab and Total Skin Electron Beam Radiotherapy in Mycosis Fungoides and Sézary… | Phase 1 | withdrawn | Aug 6, 2018 | University of Texas Southwestern Medical Center | Unable to enroll patients that met enrollment criteria. | Enrollment / accrual |
| NCT03075553 | Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma | Phase 2 | terminated | Mar 9, 2017 | Mayo Clinic | due to poor response | Other (stated, no rule matched) |
| NCT03719560 | Early Systemic Central Nervous System Prophylaxis in Diffuse Large B-cell Lymphoma(BrUOG-377) | Phase 2 | withdrawn | Oct 25, 2018 | Brown University | lack of funding | Funding |
| NCT00860171 | Iodine I 131 Monoclonal Antibody BC8 Before Autologous Stem Cell Transplant in Treating… | Phase 1 | terminated | Mar 12, 2009 | Fred Hutchinson Cancer Center | Terminated due to lack of funding | Funding |
| NCT00901927 | Bendamustine, Mitoxantrone, and Rituximab (BMR) for Patients With Untreated High Risk… | Phase 2 | terminated | May 14, 2009 | M.D. Anderson Cancer Center | Study was closed early due to toxicity | Safety / toxicity |
| NCT03266692 | Study of ACTR087 in Combination With SEA-BCMA in Subjects With Relapsed or Refractory… | Phase 1 | terminated | Aug 30, 2017 | Cogent Biosciences, Inc. | Business reasons | Sponsor / business decision |
| NCT01077518 | Ofatumumab Bendamustine Combination Compared With Bendamustine Monotherapy in Indolent…(A+B) | Phase 3 | terminated | Mar 1, 2010 | Novartis Pharmaceuticals | The study was terminated early as it did not meet the Primary efficacy objective after primary… | Efficacy / futility |
| NCT04024384 | Daratumumab as Maintenance After Peripheral Blood Stem Cell Transplantation From…(DARALLO) | Phase 2 | withdrawn | Jul 18, 2019 | Assistance Publique - Hôpitaux de Paris | Promotor decision | Other (stated, no rule matched) |
| NCT01609816 | Dasatinib for Modulating Immune System After Autologous Stem Cell Transplants for… | Phase 1 | terminated | Jun 1, 2012 | Barbara Ann Karmanos Cancer Institute | Low accrual. No Analyses were performed | Enrollment / accrual |
| NCT02756728 | A Phase I/II Study of BI-505 in Conjunction With Autologous Stem Cell Transplant in… | Phase 1 / Phase 2 | terminated | Apr 29, 2016 | BioInvent International AB | Full clinical hold from FDA | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Nov 9, 2020source: clinicaltrials